The post T. Rowe Price Files for First Actively Managed Crypto ETF appeared first on Coinpedia Fintech News T. Rowe Price, one of America’s most established asset management firms overseeing nearly $1.8 trillion in assets, has officially filed for its first-ever cryptocurrency exchange-traded fund (ETF) with the U.S. Securities and Exchange Commission (SEC).  The new T. Rowe Price Active Crypto ETF marks the firm’s first step into digital assets, moving beyond its traditional …The post T. Rowe Price Files for First Actively Managed Crypto ETF appeared first on Coinpedia Fintech News T. Rowe Price, one of America’s most established asset management firms overseeing nearly $1.8 trillion in assets, has officially filed for its first-ever cryptocurrency exchange-traded fund (ETF) with the U.S. Securities and Exchange Commission (SEC).  The new T. Rowe Price Active Crypto ETF marks the firm’s first step into digital assets, moving beyond its traditional …

T. Rowe Price Files for First Actively Managed Crypto ETF

2025/10/23 14:44
2 min read
Tuttle Capital Delays 2X Long Crypto ETFs Listing to October 10, 2025

The post T. Rowe Price Files for First Actively Managed Crypto ETF appeared first on Coinpedia Fintech News

T. Rowe Price, one of America’s most established asset management firms overseeing nearly $1.8 trillion in assets, has officially filed for its first-ever cryptocurrency exchange-traded fund (ETF) with the U.S. Securities and Exchange Commission (SEC). 

The new T. Rowe Price Active Crypto ETF marks the firm’s first step into digital assets, moving beyond its traditional mutual fund focus.

T. Rowe Price Files For Crypto ETF

According to its S-1 filing, the T. Rowe Price Active Crypto ETF will focus on “commodity-like digital assets” rather than tokenized securities, ensuring compliance with existing SEC standards. 

The fund will hold a portion of assets in cash, stablecoins, or Treasury bills to maintain liquidity. It may also participate in staking in the future if regulations allow.

Meanwhile, the actively managed fund will hold five to fifteen cryptocurrencies, including Bitcoin, Ethereum, Solana, XRP, Cardano, Avalanche, and Dogecoin. 

The ETF will be managed by T. Rowe Price Sponsor LLC, with CSC Delaware Trust Company serving as trustee to ensure regulatory compliance and auditing transparency.​

Legacy Firms Don’t Want to Miss the Crypto Wave

Nate Geraci, president of The ETF Store, highlighted the significance of the move, noting that many traditional asset managers previously missed the ETF boom. 

“Can’t overstate the significance of T. Rowe Price filing for an actively managed crypto ETF out of left field.” 

Legacy firms are now actively designing crypto strategies instead of waiting on market developments.

Regulatory Milestone Amid a Crowded ETF Landscape

With this filing, T. Rowe Price joins a rapidly growing list of established fund managers, including BlackRock, Fidelity, and VanEck—entering the digital asset ETF race. 

More than 155 crypto ETF filings, representing 35 unique digital assets, are currently awaiting SEC review, though most are delayed by the ongoing U.S. government shutdown, which has frozen fund registration timelines.​

If approved, the T. Rowe Price Active Crypto ETF would offer institutional and retail investors a regulated gateway to multi-asset digital exposure, deepening mainstream access to cryptocurrencies amid growing global ETF adoption.

Market Opportunity
Threshold Logo
Threshold Price(T)
$0.007062
$0.007062$0.007062
-0.89%
USD
Threshold (T) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03